Eternygen GmbH Closes € 8.0 million (US$ 8.3m) Series A Financing Led by Epidarex Capital
January 9, 2017
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3)